Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Evotec SE (EVT.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
42.55+0.29 (+0.69%)
At close: 5:35PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close42.26
Open41.10
Bid42.40 x 105300
Ask42.42 x 169300
Day's Range40.71 - 42.60
52 Week Range25.54 - 45.83
Volume467,669
Avg. Volume432,381
Market Cap7.4B
Beta (5Y Monthly)0.85
PE Ratio (TTM)28.44
EPS (TTM)1.50
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.81
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for EVT.DE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

      CAMBRIDGE, Mass. & HAMBURG, Germany, November 18, 2021--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx’s pipeline expansion efforts

    • ACCESSWIRE

      Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

      The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

    • ACCESSWIRE

      Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update

      * STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH * CO-OWNED PIPELINE GAINING MOMENTUM * J.POD (R) REDMOND (US) OPERATIONAL * SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END) * GUIDANCE FOR FULL-YEAR 2021 CONFIRMED * WEBCAST AND CONFERENCE CALL TODAY AT 02.

    Advertisement
    Advertisement